Company: RNAC
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001453687-25-000085
Chunk: 25

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 25
---
)Weighted-average common shares outstanding:Basic and diluted25,902,650 5,414,020 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

6

Table of Contents

Cartesian Therapeutics, Inc. and Subsidiaries

Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Deficit

(Amounts in thousands, except share data)

     Accumulated Series ASeries B  Additional other Preferred StockPreferred StockCommon stockpaid-inAccumulatedcomprehensiveStockholders’ SharesAmountSharesAmountSharesAmountcapitaldeficitlossdeficitBalance at December 31, 2024120,790.402 $— 437,927 $— 25,767,369 $3 $689,887 $(692,071)$(4,621)$(6,802)Issuance of common stock upon exercise of options— — — — 55,690 — 183 — — 183 Issuance of vested restricted stock units— — 113,042 — — — — — Stock-based compensation expense— — — — — — 2,508 — — 2,508 Currency translation adjustment— — — — — — — — 32 32 Net loss— — — — — — — (17,710)— (17,710)Balance at March 31, 2025120,790.402 $— 437,927 $— 25,936,101 $3 $692,578 $(709,781)$(4,589)$(21,789)

On April 4, 2024, the Company effected a 1-for-30 reverse split of its issued and outstanding shares of common stock, or the Reverse Stock Split. As a result of the Reverse Stock Split, all figures in this Quarterly Report on Form 10-Q relating to shares of the Company’s common stock (such as share amounts, per share amounts, and conversion rates and prices), including but not limited to, the consolidated financial statements and footnotes included herein, have been adjusted to reflect the Reverse Stock Split for all periods presented.

The accompanying notes are an integral part of these unaudited consolidated financial statements.

7

Cartesian Therapeutics, Inc